


Claims

1. Bisarylurea derivatives of formula I



10 wherein

Ar¹, Ar² are selected independently from one another from aromatic hydrocarbons containing 6 to 14 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 10 carbon atoms and one or two heteroatoms, independently selected from N, O and S,

15

E, G, M, Q and U are selected, independently from one another, from carbon atoms and nitrogen atoms, with the proviso that one or more of E, G, M, Q and U are carbon atoms and that X is bonded to a carbon atom,

20

R⁷ is independently selected from a group consisting of Het, OHet, N(R¹¹)Het, (CR⁵R⁶)ₖHet, O(CR⁵R⁶)ₖHet, N(R¹¹)(CR⁵R⁶)ₖHet, (CR⁵R⁶)ₖNR¹¹R¹², (CR⁵R⁶)ₖOR¹³, O(CR⁵R⁶)ₖNR¹¹R¹², NR¹¹(CR⁵R⁶)ₖNR¹¹R¹², O(CR⁵R⁶)ₖR¹³, NR¹¹(CR⁵R⁶)ₖR¹³, O(CR⁵R⁶)ₖOR¹³, NR¹¹(CR⁵R⁶)ₖOR¹³, (CR⁵R⁶)ₙO(CR⁵R⁶)ₖNR¹¹R¹², O(CR⁵R⁶)ₙO(CR⁵R⁶)ₖNR¹¹R¹², NR¹¹(CR⁵R⁶)ₙO(CR⁵R⁶)ₖNR¹¹R¹², (CR⁵R⁶)ₙNR¹¹(CR⁵R⁶)ₖNR¹¹R¹², O(CR⁵R⁶)ₙNR¹¹(CR⁵R⁶)ₖNR¹¹R¹², NR¹¹(CR⁵R⁶)ₙNR¹²(CR⁵R⁶)ₖNR¹¹R¹²,

25

30

5
 $(\text{CR}^5\text{R}^6)_n\text{O}(\text{CR}^5\text{R}^6)_k\text{OR}^{11}$, $\text{O}(\text{CR}^5\text{R}^6)_n\text{O}(\text{CR}^5\text{R}^6)_k\text{OR}^{11}$,
 $\text{NR}^{11}(\text{CR}^5\text{R}^6)_n\text{O}(\text{CR}^5\text{R}^6)_k\text{OR}^{12}$, $(\text{CR}^5\text{R}^6)_n\text{NR}^{11}(\text{CR}^5\text{R}^6)_k\text{OR}^{12}$,
 $\text{O}(\text{CR}^5\text{R}^6)_n\text{NR}^{11}(\text{CR}^5\text{R}^6)_k\text{OR}^{12}$,
 $\text{NR}^{12}(\text{CR}^5\text{R}^6)_n\text{NR}^{11}(\text{CR}^5\text{R}^6)_k\text{OR}^{12}$, $\text{O}(\text{CR}^5\text{R}^6)_k\text{Ar}^3\text{-NR}^{11}\text{R}^{12}$,
 SO_2R^{13} , $\text{SO}_2(\text{CR}^5\text{R}^6)_k\text{OR}^{13}$ and $\text{SO}_2(\text{CR}^5\text{R}^6)_k\text{NR}^{11}\text{R}^{12}$,
 wherein

10
 R^5 , R^6 are in each case independently from one another selected
 from H and A; or R^5 and R^6 together optionally represent an
 oxo-group; or

R^7 is selected from divalent radicals of formula $-\text{SO}_2\text{-CR}^8=\text{CR}^8-$,
 wherein both valencies are bound vicinally to Ar^1 ,

15
 n and/or k independently are 0, 1, 2, 3 or 4, preferably 1, 2, 3 or 4,
 and even more preferred is 2 or 3;

20
 R^8 , R^9 and R^{10} are independently selected from a group consisting
 of H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal,
 CH_2Hal , $\text{CH}(\text{Hal})_2$, $\text{C}(\text{Hal})_3$, NO_2 , $(\text{CH}_2)_n\text{CN}$, $(\text{CH}_2)_n\text{NR}^{11}\text{R}^{12}$,
 $(\text{CH}_2)_n\text{O}(\text{CH}_2)_k\text{NR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{NR}^{11}(\text{CH}_2)_k\text{NR}^{11}\text{R}^{12}$,
 $(\text{CH}_2)_n\text{O}(\text{CH}_2)_k\text{OR}^{11}$, $(\text{CH}_2)_n\text{NR}^{11}(\text{CH}_2)_k\text{OR}^{12}$, $(\text{CH}_2)_n\text{COOR}^{13}$,
 $(\text{CH}_2)_n\text{COR}^{13}$, $(\text{CH}_2)_n\text{CONR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{NR}^{11}\text{COR}^{13}$,
 $(\text{CH}_2)_n\text{NR}^{11}\text{CONR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{NR}^{11}\text{SO}_2\text{A}$,
 25
 $(\text{CH}_2)_n\text{SO}_2\text{NR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{S}(\text{O})_u\text{R}^{13}$, $(\text{CH}_2)_n\text{OC}(\text{O})\text{R}^{13}$,
 $(\text{CH}_2)_n\text{COR}^{13}$, $(\text{CH}_2)_n\text{SR}^{11}$, $\text{CH}=\text{N-OA}$, $\text{CH}_2\text{CH}=\text{N-OA}$,
 $(\text{CH}_2)_n\text{NHOA}$, $(\text{CH}_2)_n\text{CH}=\text{N-R}^{11}$, $(\text{CH}_2)_n\text{OC}(\text{O})\text{NR}^{11}\text{R}^{12}$,
 $(\text{CH}_2)_n\text{NR}^{11}\text{COOR}^{13}$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{OR}^{13}$,
 $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{OCF}_3$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{C}(\text{R}^{13})\text{HCOOR}^{12}$,
 30
 $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{C}(\text{R}^{13})\text{HCOOR}^{11}$,
 $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{N}(\text{R}^{12})\text{CH}_2\text{COOR}^{11}$,
 $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{NR}^{11}\text{R}^{12}$, $\text{CH}=\text{CHCOOR}^{13}$,

5 CH=CHCH₂NR¹¹R¹², CH=CHCH₂NR¹¹R¹², CH=CHCH₂OR¹³,
 (CH₂)_nN(COOR¹³)COOR¹⁴, (CH₂)_nN(CONH₂)COOR¹³,
 (CH₂)_nN(CONH₂)CONH₂, (CH₂)_nN(CH₂COOR¹³)COOR¹⁴,
 (CH₂)_nN(CH₂CONH₂)COOR¹³, (CH₂)_nN(CH₂CONH₂)CONH₂,
 (CH₂)_nCHR¹³COR¹⁴, (CH₂)_nCHR¹³COOR¹⁴,
 (CH₂)_nCHR¹³CH₂OR¹⁴, (CH₂)_nOCN and (CH₂)_nNCO, wherein

10 R¹¹, R¹² are independently selected from a group consisting of H, A,
 C(O)A, (CH₂)_mAr³, C(O)(CH₂)_mAr³, (CH₂)_mHet,
 C(O)(CH₂)_mHet and S(O)_uA, or in NR¹¹R¹², R¹¹ and R¹² form,
 together with the N-atom they are bound to, a 5-, 6- or 7-
 membered heterocyclus which optionally contains 1 or 2
 additional hetero atoms, selected from N, O and S, which
 optionally is substituted by one or more substituent, selected
 15 from A, R¹³, =O, =S and =N-R¹⁴,

R¹³, R¹⁴ are independently selected from a group consisting of H, Hal,
 A, (CH₂)_mAr⁴ and (CH₂)_mHet,

20 A is selected from the group consisting of alkyl, alkenyl,
 cycloalkyl, alkylenecycloalkyl, alkoxy, alkoxyalkyl and
 saturated heterocyclyl, preferably from the group consisting
 of alkyl, alkenyl, cycloalkyl, alkylenecycloalkyl, alkoxy and
 alkoxyalkyl,

25 Ar³, Ar⁴ are independently from one another aromatic hydrocarbon
 residues comprising 5 to 12 and preferably 5 to 10 carbon
 atoms which are optionally substituted by one or more
 substituents, selected from a group consisting of A, Hal, NO₂,
 30 CN, OR¹⁵, NR¹⁵R¹⁶, COOR¹⁵, CONR¹⁵R¹⁶, NR¹⁵COR¹⁶,
 NR¹⁵CONR¹⁵R¹⁶, NR¹⁶SO₂A, COR¹⁵, SO₂NR¹⁵R¹⁶, S(O)_uA
 and OOCR¹⁵,

- 5 Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one or more substituents, selected from a group consisting of A, C(O)A, R¹³, =O, =S, =N-R¹⁴, Hal, NO₂, CN, OR¹⁵, NR¹⁵R¹⁶, COOR¹⁵, CONR¹⁵R¹⁶, NR¹⁵COR¹⁶, NR¹⁵CONR¹⁵R¹⁶, NR¹⁶SO₂A, COR¹⁵, SO₂NR¹⁵R¹⁶, S(O)_uA and OOCR¹⁵,
- 10 R¹⁵, R¹⁶ are independently selected from a group consisting of H, A, and (CH₂)_mAr⁶, wherein
- 15 Ar⁶ is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from a group consisting of methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH₂ and CF₃,
- k, n and m are independently of one another 0, 1, 2, 3, 4, or 5,
- 20 X represents a bond or is (CR¹¹R¹²)_h, or (CHR¹¹)_h-Q-(CHR¹²)_i, wherein
- 25 Q is selected from a group consisting of O, S, N-R¹⁵, (CHal₂)_j, (O-CHR¹⁸)_j, (CHR¹⁸-O)_j, CR¹⁸=CR¹⁹, (O-CHR¹⁸CHR¹⁹)_j, (CHR¹⁸CHR¹⁹-O)_j, C=O, C=S, C=NR¹⁵, CH(OR¹⁵), C(OR¹⁵)(OR²⁰), C(=O)O, OC(=O), OC(=O)O, C(=O)N(R¹⁵), N(R¹⁵)C(=O), OC(=O)N(R¹⁵), N(R¹⁵)C(=O)O, CH=N-O, CH=N-NR¹⁵, OC(O)NR¹⁵, NR¹⁵C(O)O, S=O, SO₂, SO₂NR¹⁵ and NR¹⁵SO₂, wherein
- 30 h, i are independently from each other 0, 1, 2, 3, 4, 5, or 6, and
- j is 1, 2, 3, 4, 5, or 6,

Y is selected from O, S, NR^{21} , $\text{C(R}^{22}\text{)-NO}_2$, $\text{C(R}^{22}\text{)-CN}$ and C(CN)_2 , wherein

5 R^{21} is independently selected from the meanings given for R^{13} , R^{14} and

R^{22} is independently selected from the meanings given for R^{11} , R^{12} ,

10

g is 1, 2 or 3, preferably 1 or 2,

p, r are independently from one another 0, 1, 2, 3, 4 or 5,

15

q is 0, 1, 2, 3 or 4, preferably 0, 1 or 2,

u is 0, 1, 2 or 3, preferably 0, 1 or 2,

and

20

Hal is independently selected from a group consisting of F, Cl, Br and I;

and the pharmaceutically acceptable derivatives, salts and solvates thereof.

25

2. Bisarylurea derivatives according to claim 1,

wherein

30

Ar^1 , Ar^2 are selected independently from one another from aromatic hydrocarbons containing 6 to 10 and especially 6 carbon

atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 8 and especially 4 to 6 carbon atoms and one or two heteroatoms, independently selected from N, O and S and especially selected from N and O,

5

R^7 is independently selected from a group consisting of Het, OHet, $N(R^{11})\text{Het}$, $(\text{CR}^5\text{R}^6)_k\text{Het}$, $\text{O}(\text{CR}^5\text{R}^6)_k\text{Het}$, $N(R^{11})(\text{CR}^5\text{R}^6)_k\text{Het}$, $(\text{CR}^5\text{R}^6)_k\text{NR}^{11}\text{R}^{12}$, $(\text{CR}^5\text{R}^6)_k\text{OR}^{13}$, $\text{O}(\text{CR}^5\text{R}^6)_k\text{NR}^{11}\text{R}^{12}$, $\text{NR}^{11}(\text{CR}^5\text{R}^6)_k\text{NR}^{11}\text{R}^{12}$, $\text{O}(\text{CR}^5\text{R}^6)_k\text{R}^{13}$, $\text{NR}^{11}(\text{CR}^5\text{R}^6)_k\text{R}^{13}$, $\text{O}(\text{CR}^5\text{R}^6)_k\text{OR}^{13}$, $\text{NR}^{11}(\text{CR}^5\text{R}^6)_k\text{OR}^{13}$, $\text{O}(\text{CR}^5\text{R}^6)_n\text{O}(\text{CR}^5\text{R}^6)_k\text{NR}^{11}\text{R}^{12}$, $\text{NR}^{11}(\text{CR}^5\text{R}^6)_n\text{O}(\text{CR}^5\text{R}^6)_k\text{NR}^{11}\text{R}^{12}$, $\text{O}(\text{CR}^5\text{R}^6)_n\text{NR}^{11}(\text{CR}^5\text{R}^6)_k\text{NR}^{11}\text{R}^{12}$, $\text{NR}^{11}(\text{CR}^5\text{R}^6)_n\text{NR}^{12}(\text{CR}^5\text{R}^6)_k\text{NR}^{11}\text{R}^{12}$, $\text{O}(\text{CR}^5\text{R}^6)_n\text{O}(\text{CR}^5\text{R}^6)_k\text{OR}^{11}$, $\text{NR}^{11}(\text{CR}^5\text{R}^6)_n\text{O}(\text{CR}^5\text{R}^6)_k\text{OR}^{12}$, $\text{O}(\text{CR}^5\text{R}^6)_n\text{NR}^{11}(\text{CR}^5\text{R}^6)_k\text{OR}^{12}$ and $\text{NR}^{12}(\text{CR}^5\text{R}^6)_n\text{NR}^{11}(\text{CR}^5\text{R}^6)_k\text{OR}^{12}$, $\text{O}(\text{CR}^5\text{R}^6)_k\text{Ar}^3\text{-NR}^{11}\text{R}^{12}$, SO_2R^{13} , $\text{SO}_2(\text{CR}^5\text{R}^6)_k\text{OR}^{13}$ and $\text{SO}_2(\text{CR}^5\text{R}^6)_k\text{NR}^{11}\text{R}^{12}$, wherein

10

15

20

R^5 , R^6 are in each case independently from one another selected from H and A; or R^5 and R^6 together optionally represent an oxo-group; or

25

R^7 is selected from divalent radicals of formula $-\text{SO}_2\text{-CR}^8=\text{CR}^8-$, wherein both valencies are bound vicinally to Ar^1 , and

n and/or k independently are 0, 1, 2, 3 or 4, preferably 1, 2, 3 or 4, and even more preferred are 2 or 3;

30

R^8 , R^9 and R^{10} are independently selected from a group consisting of H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal,

CH_2Hal , $\text{CH}(\text{Hal})_2$, $\text{C}(\text{Hal})_3$, NO_2 , $(\text{CH}_2)_n\text{CN}$, $(\text{CH}_2)_n\text{NR}^{11}\text{R}^{12}$,
 $(\text{CH}_2)_n\text{O}(\text{CH}_2)_k\text{NR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{NR}^{11}(\text{CH}_2)_k\text{NR}^{11}\text{R}^{12}$,
 $(\text{CH}_2)_n\text{O}(\text{CH}_2)_k\text{OR}^{11}$, $(\text{CH}_2)_n\text{NR}^{11}(\text{CH}_2)_k\text{OR}^{12}$, $(\text{CH}_2)_n\text{COR}^{13}$,
 $(\text{CH}_2)_n\text{COOR}^{13}$, $(\text{CH}_2)_n\text{CONR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{NR}^{11}\text{COR}^{13}$,
5 $(\text{CH}_2)_n\text{NR}^{11}\text{CONR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{NR}^{11}\text{SO}_2\text{A}$,
 $(\text{CH}_2)_n\text{SO}_2\text{NR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{S}(\text{O})_u\text{R}^{13}$, $(\text{CH}_2)_n\text{OC}(\text{O})\text{R}^{13}$,
 $(\text{CH}_2)_n\text{COR}^{13}$, $(\text{CH}_2)_n\text{SR}^{11}$, $(\text{CH}_2)_n\text{NHOA}$,
 $(\text{CH}_2)_n\text{NR}^{11}\text{COOR}^{13}$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{OR}^{13}$,
 $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{OCF}_3$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{C}(\text{R}^{13})\text{HCOOR}^{12}$,
10 $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{C}(\text{R}^{13})\text{HCOR}^{11}$, $(\text{CH}_2)_n\text{N}(\text{COOR}^{13})\text{COOR}^{14}$,
 $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{COOR}^{13}$, $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{CONH}_2$,
 $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{COOR}^{13})\text{COOR}^{14}$,
 $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{COOR}^{13}$, $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{CONH}_2$,
 $(\text{CH}_2)_n\text{CHR}^{13}\text{COR}^{14}$, $(\text{CH}_2)_n\text{CHR}^{13}\text{COOR}^{14}$ and
15 $(\text{CH}_2)_n\text{CHR}^{13}\text{CH}_2\text{OR}^{14}$, wherein

n and/or k independently are 0, 1, 2, 3 or 4, preferably 0, 1, 2 or 3,
and even more preferred are 0 or 2;

20 X represents a bond or is $(\text{CR}^{11}\text{R}^{12})_h$, or $(\text{CHR}^{11})_h\text{-Q-(CHR}^{12})_i$,
wherein

25 Q is selected from a group consisting of O , S , N-R^{15} , $(\text{CHal}_2)_j$,
 $(\text{O-CHR}^{18})_j$, $(\text{CHR}^{18}\text{-O})_j$, $\text{CR}^{18}=\text{CR}^{19}$, $(\text{O-CHR}^{18}\text{CHR}^{19})_j$,
 $(\text{CHR}^{18}\text{CHR}^{19}\text{-O})_j$, C=O , C=NR^{15} , $\text{CH}(\text{OR}^{15})$, $\text{C}(\text{OR}^{15})(\text{OR}^{20})$,
 $\text{C(=O)N(R}^{15})$, $\text{N(R}^{15})\text{C(=O)}$, CH=N-NR^{15} , S=O , SO_2 , $\text{SO}_2\text{NR}^{15}$
and $\text{NR}^{15}\text{SO}_2$, wherein

30 h, i are independently from each other 0, 1, 2, 3, 4, 5 or 6,
preferably 0, 1, 2 or 3 and

j is 1, 2, 3, 4, 5 or 6, preferably 1, 2, 3 or 4,

g is 1 or 2, preferably 1,

p is 1, 2 or 3, preferably 1 or 2, and

r is 0, 1, 2, or 3, preferably 0, 1 or 2;

and the pharmaceutically acceptable derivatives, solvates, salts and stereoisomers thereof

3. Bisarylurea derivatives according to claim 1 or 2,


wherein

R^7 is independently selected from a group consisting of Het, OHet, $N(R^{11})\text{Het}$, $(CR^5R^6)_k\text{Het}$, $O(CR^5R^6)_k\text{Het}$, $N(R^{11})(CR^5R^6)_k\text{Het}$, $(CR^5R^6)_kNR^{11}R^{12}$, $(CR^5R^6)_kOR^{13}$, $O(CR^5R^6)_kNR^{11}R^{12}$, $NR^{11}(CR^5R^6)_kNR^{11}R^{12}$, $O(CR^5R^6)_kR^{13}$, $NR^{11}(CR^5R^6)_kR^{13}$, $O(CR^5R^6)_kOR^{13}$, $NR^{11}(CR^5R^6)_kOR^{13}$, $O(CR^5R^6)_kAr^3-NR^{11}R^{12}$, SO_2R^{13} , $SO_2(CR^5R^6)_kOR^{13}$, $SO_2(CR^5R^6)_kNR^{11}R^{12}$ and divalent radicals of formula $-SO_2-CR^8=CR^8-$, wherein both valencies are bound vicinally to Ar^1 ; and more preferably from OHet, $N(R^{11})\text{Het}$, $(CR^5R^6)_k\text{Het}$, $O(CR^5R^6)_k\text{Het}$, $N(R^{11})(CR^5R^6)_k\text{Het}$, $O(CR^5R^6)_kNR^{11}R^{12}$, $NR^{11}(CR^5R^6)_kNR^{11}R^{12}$, $O(CR^5R^6)_kOR^{13}$ and $NR^{11}(CR^5R^6)_kOR^{13}$, $O(CR^5R^6)_kAr^3-NR^{11}R^{12}$, SO_2R^{13} , $SO_2(CR^5R^6)_kOR^{13}$, $SO_2(CR^5R^6)_kNR^{11}R^{12}$ and divalent radicals of formula $-SO_2-CR^8=CR^8-$, wherein both valencies are bound vicinally to Ar^1 , and

n and k are independently from one another 0, 1, 2, 3 or 4.


4. Bisarylurea derivative according to one of the claims 1 to 3, selected from the compounds of formula Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, IL, Im, In, Io, Ip, Iq, Ir, Is, It, Iu, Iv, Iw, Ix, Iy, Iz and Iaa to Iuu,

5




Ia

10




Ib

15




Ic

20




Id

25




Ie

30




If

243




Ig

5




Ih

10




Ii

15



Ij

20




Ik

25

30


244

5




IL

10




Im

15




In

20



Io


25




Ip

30


245




Iq



Ir




Is



It


246

5




Iu

10




Iv

15




Iw

20



Ix


25



Iy


30

247




Iz

5




Iaa

10




Ibb

15




Icc

20



Idd


25



Iee


30

248




Iff

5




Igg

10




Ihh

15




Iij

20



Ijj


25



Ikk


30

249




ILL

5




Imm

10




Inn

15




Ioo

20




lpp

25




lqq


30




Irr



Iss



Itt



Iuu

wherein R^7 , R^8 , R^{11} , R^{12} , R^{13} , Y , X , R^9 , A , D , g , p and q are as defined in one of the claims 1 to 3, R^{10} is H or as defined in one of the claims 1 to 3; and A and D are CR^5R^6 , wherein R^5 and R^6 are as defined in claim 1, and the pharmaceutically acceptable derivatives, salts and solvates thereof.

5. Bisarylurea derivative according to claim one of the claims 1 to 4, selected from 4-(4-{3-[4-Chloro-5-methyl-2-(2-methylamino-ethoxy)-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide; 4-(4-{3-[Chloro-(2-methylamino-ethoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;

4-(4-{3-[(2-Methylamino-ethoxy)-trifluoromethyl-phenyl]-ureido}-
phenoxy)-pyridine-2-carboxylic acid methylamide;
4-(4-{3-[Chloro-(2-dimethylamino-ethoxy)-trifluoromethyl-phenyl]-
ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
5 4-(4-{3-[Chloro-(2-diethylamino-ethoxy)-trifluoromethyl-phenyl]-ureido}-
phenoxy)-pyridine-2-carboxylic acid methylamide;
4-(4-{3-[Chloro-(2-morpholin-4-yl-ethoxy)-trifluoromethyl-phenyl]-
ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
4-(4-{3-[Chloro-(2-pyrrolidin-1-yl-ethoxy)-trifluoromethyl-phenyl]-ureido}-
10 phenoxy)-pyridine-2-carboxylic acid methylamide;
4-(4-{3-[Chloro-(piperidin-4-yl-ethoxy)-trifluoromethyl-phenyl]-ureido}-
phenoxy)-pyridine-2-carboxylic acid methylamide;
4-(4-{3-[(2-Amino-ethoxy)-chloro-trifluoromethyl-phenyl]-ureido}-
phenoxy)-pyridine-2-carboxylic acid methylamide;
15 4-(4-{3-[2-(2-Amino-ethoxy)-4-chloro-5-methyl-phenyl]-ureido}-
phenoxy)-pyridine-2-carboxylic acid methylamide;
4-(4-{3-[(2-Amino-ethoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-
pyridine-2-carboxylic acid methylamide;
4-(4-{3-[Chloro-(2-piperazin-1-yl-ethoxy)-trifluoromethyl-phenyl]-ureido}-
20 phenoxy)-pyridine-2-carboxylic acid methylamide;
4-(3-{3-[Chloro-(2-diethylamino-ethoxy)-trifluoromethyl-phenyl]-ureido}-
phenoxy)-pyridine-2-carboxylic acid methylamide;
4-(4-{3-[4-Chloro-2-(2-dimethylamino-ethoxy)-5-methyl-phenyl]-ureido}-
phenoxy)-pyridine-2-carboxylic acid methylamide;
25 4-(4-{3-[4-Chloro-2-(2-diethylamino-ethoxy)-5-methyl-phenyl]-ureido}-
phenoxy)-pyridine-2-carboxylic acid methylamide;
4-(4-{3-[4-Chloro-5-methyl-2-(2-morpholin-4-yl-ethoxy)-phenyl]-ureido}-
phenoxy)-pyridine-2-carboxylic acid methylamide;
4-(4-{3-[4-Chloro-5-methyl-2-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-ureido}-
30 phenoxy)-pyridine-2-carboxylic acid methylamide;
4-(3-{3-[Chloro-(2-morpholin-4-yl-ethoxy)-trifluoromethyl-phenyl]-
ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;

- 4-(4-{3-[(2-Pyrrolidin-1-yl-ethoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 4-(4-{3-[(2-Morpholin-4-yl-ethoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 5 4-(4-{3-[(2-Diethylamino-ethoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acidmethylamide;
- 4-(4-{3-[(2-Dimethylamino-ethoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 10 4-(4-{3-[4-Chloro-5-methyl-2-(2-piperazin-1-yl-ethoxy)-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 4-(4-{3-[4-Chloro-5-methyl-2-(piperidin-4-yloxy)-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acidmethylamide;
- 4-(4-{3-[(2-Piperazin-1-yl-ethoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 15 4-(4-{3-[(Piperidin-4-yloxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 4-(4-{3-[(Pyrrolidin-2-ylmethoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 4-(3-{3-[Chloro-(2-pyrrolidin-1-yl-ethoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 20 4-(4-{3-[(2-Amino-2-methyl-propoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 4-(3-{3-[(2-Amino-ethoxy)-chloro-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acidmethylamide;
- 25 4-(3-{3-[(2-Methylamino-ethoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acidmethylamide;
- 4-(4-{3-[(2-Isopropylamino-ethoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 4-(3-{3-[4-Chloro-5-methyl-2-(2-methylamino-ethoxy)-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 30 4-(3-{3-[Chloro-(2-methylamino-ethoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;

- 4-(3-{3-[Chloro-(2-dimethylamino-ethoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 4-(3-{3-[Chloro-(2-piperazin-1-yl-ethoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 5 4-(3-{3-[Chloro-(piperidin-4-yloxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 4-(3-{3-[2-(2-Amino-ethoxy)-4-chloro-5-methyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 4-(3-{3-[(2-Dimethylamino-ethoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 10 4-(3-{3-[4-Chloro-2-(2-dimethylamino-ethoxy)-5-methyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 4-(3-{3-[4-Chloro-5-methyl-2-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 15 4-(3-{3-[(2-Pyrrolidin-1-yl-ethoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 4-(3-{3-[(Piperidin-4-yloxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 4-(3-{3-[4-Chloro-5-methyl-2-(piperidin-4-yloxy)-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 20 4-(3-{3-[(2-Amino-2-methyl-propoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 4-(3-{3-[(2-Isopropylamino-ethoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 25 4-(3-{3-[(Pyrrolidin-2-ylmethoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 4-(3-{3-[(2-Amino-ethoxy)-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;
- 1-[3-Methyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-3-[4-(pyridin-4-yloxy)-phenyl]-urea;
- 30 1-[4-(Pyridin-4-yloxy)-phenyl]-3-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-urea;

4-(4-{3-[4-(2-Pyrrolidin-1-yl-ethoxy)-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;

1-[3-Chloro-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-3-[4-(pyridin-4-yloxy)-phenyl]-urea;

5 4-(4-{3-[4-(Piperidin-4-yloxy)-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;

1-[4-(Piperidin-4-yloxy)-phenyl]-3-[4-(pyridin-4-yloxy)-phenyl]-urea;

4-(4-{3-[4-(2-Pyrrolidin-1-yl-ethoxy)-3-trifluoromethyl-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;

10 1-[4-(2-Dimethylamino-ethoxy)-phenyl]-3-[4-(pyridin-4-yloxy)-phenyl]-urea;

1-[4-(Pyridin-4-yloxy)-phenyl]-3-[4-(2-pyrrolidin-1-yl-ethoxy)-3-trifluoromethyl-phenyl]-urea;

15 4-(4-{3-[4-(Pyrrolidin-3-yloxy)-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;

N-[4-(5-Chloro-2-{3-[4-(pyridin-4-yloxy)-phenyl]-ureido}-phenoxy)-phenyl]-acetamide;

4-(2-Chloro-4-{3-[4-(pyridin-4-yloxy)-phenyl]-ureido}-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester;

20 4-(2-Chloro-4-{3-[4-(2-methylcarbamoyl-pyridin-4-yloxy)-phenyl]-ureido}-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester;

4-(4-{3-[4-(2-Dimethylamino-ethoxy)-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;

25 4-(4-{3-[2-Chloro-5-(2-diethylamino-ethoxy)-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;

4-(4-{3-[4-Methoxy-3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;

4-(4-{3-[3-Chloro-4-(piperidin-4-yloxy)-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic acid methylamide;

30 1-[3-Chloro-4-(piperidin-4-yloxy)-phenyl]-3-[4-(pyridin-4-yloxy)-phenyl]-urea;

4-(4-{3-[2-Methyl-3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-ureido}-phenoxy)-

- pyridine-2-carboxylic acid methylamide;
 (4-{3-[3-(Pyridin-4-yloxy)-phenyl]-ureido}-phenoxy)-pyridine-2-carboxylic
 acid methylamide;
 4-{4-[3-(5-Carbamoyl-4-chloro-2-fluoro-phenyl)-ureido]-phenoxy}-
 5 pyridine-2-carboxylic acid methylamide;
 4-[2-(4-{3-[4-(2-Methylcarbamoyl-pyridin-4-yloxy)-phenyl]-ureido}-
 phenoxy)-ethyl]-piperazine-1-carboxylic acid tert-butyl ester;
 4-(4-{3-[4-(2-Piperazin-1-yl-ethoxy)-phenyl]-ureido}-phenoxy)-pyridine-
 2-carboxylic acid methylamide;
 10 4-(4-{3-[4-(2,5-Dioxo-pyrrolidin-1-yl)-3-trifluoromethyl-phenyl]-ureido}-
 phenoxy)-pyridine-2-carboxylic acid methylamide;
 4-(4-{3-[2-(4-Acetylamino-phenoxy)-4-chloro-phenyl]-ureido}-phenoxy)-
 pyridine-2-carboxylic acid methylamide;
 4-{4-[3-(2-tert-Butoxy-5-trifluoromethyl-phenyl)-ureido]-phenoxy}-
 15 pyridine-2-carboxylic acid methylamide;
 4-(4-{3-[4-(Piperidin-4-yloxy)-3-trifluoromethyl-phenyl]-ureido}-phenoxy)-
 pyridine-2-carboxylic acid methylamide;
 1-[4-(Piperidin-4-yloxy)-3-trifluoromethyl-phenyl]-3-[4-(pyridin-4-yloxy)-
 phenyl]-urea;
 20 4-{4-[3-(2-Hydroxy-5-trifluoromethyl-phenyl)-ureido]-phenoxy}-pyridine-
 2-carboxylic acid methylamide;
 4-(4-{3-[3-Cyano-4-(piperidin-4-yloxy)-phenyl]-ureido}-phenoxy)-
 pyridine-2-carboxylic acid methylamide;
 4-{4-[3-(2-Dimethylamino-5-trifluoromethyl-phenyl)-ureido]-phenoxy}-
 25 pyridine-2-carboxylic acid methylamide;
 4-{4-[3-(2-Chloro-5-trifluoromethanesulfonyl-phenyl)-ureido]-phenoxy}-
 pyridine-2-carboxylic acid methylamide;
 4-{4-[3-(1,1-Dioxo-1H-116-benzo[b]thiophen-6-yl)-ureido]-phenoxy}-
 pyridine-2-carboxylic acid methylamide;
 30 4-(4-{3-[3-(2-Hydroxy-ethanesulfonyl)-phenyl]-ureido}-phenoxy)-
 pyridine-2-carboxylic acid methylamide;
 4-{4-[3-(2-Fluoro-5-methanesulfonyl-phenyl)-ureido]-phenoxy}-pyridine-

- 2-carboxylic acid methylamide;
4-{4-[3-(5-Methanesulfonyl-2-methoxy-phenyl)-ureido]-phenoxy}-
pyridine-2-carboxylic acid methylamide;
4-(4-{3-[2-(2-Methoxy-ethoxy)-5-trifluoromethyl-phenyl]-ureido}-
5 phenoxy)-pyridine-2-carboxylic acid methylamide;
4-(4-{3-[2-(2-Methanesulfonylamino-ethyl)-5-trifluoromethyl-phenyl]-
ureido]-phenoxy)-pyridine-2-carboxylic acid methylamide;
4-{4-[3-(3-Trifluoromethanesulfonyl-phenyl)-ureido]-phenoxy}-pyridine-
2-carboxylic acid methylamide;
10 4-{4-[3-(2-Carbamoylmethyl-5-trifluoromethyl-phenyl)-ureido]-phenoxy}-
pyridine-2-carboxylic acid methylamide;
4-(2-{3-[4-(2-Methylcarbamoyl-pyridin-4-yloxy)-phenyl]-ureido}-4-
trifluoromethyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester;
4-{4-[3-(2-Morpholin-4-yl-5-trifluoromethyl-phenyl)-ureido]-phenoxy}-
15 pyridine-2-carboxylic acid methylamide;
4-{4-[3-(2-Piperazin-1-yl-5-trifluoromethyl-phenyl)-ureido]-phenoxy}-
pyridine-2-carboxylic acid methylamide;
4-(4-{3-[2-(Acetylamino-methyl)-5-trifluoromethyl-phenyl]-ureido}-
phenoxy)-pyridine-2-carboxylic acid methylamide;
20 4-(4-{3-[2-(2-Acetylamino-ethyl)-5-trifluoromethyl-phenyl]-ureido}-
phenoxy)-pyridine-2-carboxylic acid methylamide;
4-{4-[3-(4-Methoxy-biphenyl-3-yl)-ureido]-phenoxy}-pyridine-2-
carboxylic acid methylamide;
4-{4-[3-(5-Cyclohexyl-2-methoxy-phenyl)-ureido]-phenoxy}-pyridine-2-
25 carboxylic acid methylamide;
4-(4-{3-[2-Methoxy-5-(1-methyl-1-phenyl-ethyl)-phenyl]-ureido}-
phenoxy)-pyridine-2-carboxylic acid methylamide;
4-{4-[3-(2-Methoxy-5-phenylcarbamoyl-phenyl)-ureido]-phenoxy}-
pyridine-2-carboxylic acid methylamide;
30 4-Methoxy-3-{3-[4-(2-methylcarbamoyl-pyridin-4-yloxy)-phenyl]-ureido}-
benzoic acid methyl ester;
5-Methoxy-2-methyl-4-{3-[4-(2-methylcarbamoyl-pyridin-4-yloxy)-

phenyl]-ureido}-benzenesulfonic acid;

4-{4-[3-(4-Benzoyloxy-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-

pyridine-2-carboxylic acid methylamide;

1-(4-Benzoyloxy-3-trifluoromethyl-phenyl)-3-[4-(pyridin-4-yloxy)-phenyl]-

5 urea;

4-{4-[3-(4-Hydroxy-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-pyridine-

2-carboxylic acid methylamide;

4-{4-[3-(5-Carbamoyl-2-methoxy-phenyl)-ureido]-phenoxy}-pyridine-2-

carboxylic acid methylamide;

10 1-(4-Hydroxy-3-trifluoromethyl-phenyl)-3-[4-(pyridin-4-yloxy)-phenyl]-

urea;

4-(2-{3-[4-(2-Methylcarbamoyl-pyridin-4-yloxy)-phenyl]-ureido}-phenyl)-

piperazine-1-carboxylic acid tert-butyl ester;

4-{4-[3-(2-Piperazin-1-yl-phenyl)-ureido]-phenoxy}-pyridine-2-carboxylic

15 acid methylamide;

4-[4-(3-{2-[(Pyridine-4-carbonyl)-amino]-5-trifluoromethyl-phenyl}-

ureido)-phenoxy]-pyridine-2-carboxylic acid methylamide;

and the pharmaceutically acceptable derivatives, salts and solvates

20 thereof.

6. Bisarylurea derivative according to one of the claims 1 to 5 as a medicament.

25 7. Bisarylurea derivative according to one of the claims 1 to 5 as a kinase inhibitor.

8. Bisarylurea derivative according to claim 7, characterized in that the kinases are selected from raf-kinases, Tie-kinases, PDGFR-kinases and VEGFR-kinases.


30

9. Pharmaceutical composition, characterised in that it contains one or more compounds according to one of the claims 1 to 5.
- 5 10. Pharmaceutical composition according to claim 9, characterised in that it contains one or more additional compounds, selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutical active ingredients other than the compounds according to one of the claims 1 to 5.
- 10 11. Process for the manufacture of a pharmaceutical composition, characterised in that one or more compounds according to one of the claims 1 to 5 and one or more compounds, selected from the group consisting of carriers, excipients, auxiliaries and pharmaceutical active ingredients other than the compounds according to one of the claims 1
15 to 5, is processed by mechanical means into a pharmaceutical composition that is suitable as dosageform for application and/or administration to a patient.
- 20 12. Use of a compound according to one of the claims 1 to 5 as a pharmaceutical.
13. Use of a compound according to one of the claims 1 to 5 in the treatment and/or prophylaxis of disorders.
- 25 14. Use of a compound according to one of the claims 1 to 5 for producing a pharmaceutical composition for the treatment and/or prophylaxis of disorders.
- 30 15. Use according to claim 13 or 14, characterised in that the disorders are caused, mediated and/or propagated by one or more kinases, selected from raf-kinases, Tie-kinases, PDGFR-kinases and VEGFR-kinases.

16. Use according to claim 13, 14 or 15, characterised in that the disorders are selected from the group consisting of hyperproliferative and nonhyperproliferative disorders.
- 5 17. Use according to claim 13, 14, 15 or 16, characterised in that the disorder is cancer.
18. Use according to claim 13, 14, 15 or 16, characterised in that the disorder is noncancerous.
- 10 19. Use according to claim 13, 14, 15, 16 or 18, characterised in that the disorders are selected from the group consisting of psoriasis, arthritis, inflammation, endometriosis, scarring, *Helicobacter pylori* infection, Influenza A, benign prostatic hyperplasia, immunological diseases, autoimmune diseases and immunodeficiency diseases.
- 15 20. Use according to one of the claims 13 to 17, characterised in that the disorders are selected from the group consisting of melanoma, brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, ovarian cancer, ovary cancer, uterine cancer, prostate cancer, thyroid cancer, lymphoma, chronic leukaemia and acute leukaemia.
- 20 21. Use according to one of the claims 13 to 18, characterised in that the disorders are selected from the group consisting of arthritis, restenosis; fibrotic disorders; mesangial cell proliferative disorders, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, organ transplant rejection, glomerulopathies, metabolic disorders, inflammation, solid tumors, rheumatic arthritis, diabetic retinopathy, and neurodegenerative diseases.
- 25 30

- 5 22. Use according to one of the claims 13 to 16, characterised in that the disorders are selected from the group consisting of rheumatoid arthritis, inflammation, autoimmune disease, chronic obstructive pulmonary disease, asthma, inflammatory bowel disease, fibrosis, atherosclerosis, restenosis, vascular disease, cardiovascular disease, inflammation, renal disease and angiogenesis disorders.
- 10 23. Use of a compound according to one of the claims 1 to 5 as a kinase inhibitor.
- 15 24. Use according to claim 23, characterised in that the kinase is selected from the group consisting of raf-kinases, Tie-kinases, PDGFR-kinases, VEGFR-kinases and p38-kinases.
- 20 25. Method for the treatment and/or prophylaxis of disorders, characterised in that one or more compounds according to one of the claims 1 to 5 is administered to a patient in need of such a treatment.
- 25 26. Method according to claim 25, characterised in that the one or more compounds according to one of the claims claim 1 to 5 are administered as a pharmaceutical composition according to claim 9 or 10.
- 30 27. Method for the treatment and/or prophylaxis of disorders according to claim 26, characterised in that the disorders are as defined in one of the claims 15 to 22.
28. Method for the treatment according to claim 27, characterised in that the disorder is cancerous cell growth mediated by raf-kinase, Tie kinases, PDGFR kinases and/or VEGFR kinases.
29. Method for producing compounds of formula I, characterised in that

a) a compound of formula II,




wherein

L^1 and L^2 either independently from one another represent a leaving group, or together represent a leaving group, and Y is as defined above/below,

is reacted with

b) a compound of formula III




wherein

L^3 and L^4 are independently from one another H or a metal ion, and wherein R^7 , R^8 , g, p and Ar^1 are as defined in claim 1,

and

c) a compound of formula IV,

262



5

wherein

L^5 and L^6 are independently from one another H or a metal ion,
and E, G, M, Q, U, R^9 , q, X, Ar^2 , R^{10} and r are as
defined in claim 1,


10

and optionally

d) isolating and/or treating the compound of formula I obtained by
said reaction with an acid, to obtain the salt thereof.

15

30. Compound of formula III,




20

wherein

L^3 and L^4 are independently from one another H or a metal ion, and
wherein R^7 , R^8 , g, p and Ar^1 are as defined in claim 1.

25

31. Compound of formula IV,



30

wherein

L^5 and L^6 are independently from one another H or a metal ion, and E,

5 G, M, Q, U, R^9 , q, X, Ar^2 , R^{10} and r are as defined in claim 1.

10

15

20

25

30